Simister K
National Prescribing Centre, 70 Pembroke Place, Liverpool L69 3GF, UK.
Ann Rheum Dis. 2000 Nov;59 Suppl 1(Suppl 1):i38-40. doi: 10.1136/ard.59.suppl_1.i38.
The role of the various agencies involved in the managed introduction of new drugs in the United Kingdom is discussed, particularly with regard to the work of the National Institute for Clinical Excellence (NICE). The process by which the National Health Service in the UK identifies key new drug technologies of major clinical, financial and service significance is discussed. This includes the decision making process for selection of products for appraisal by NICE. The appraisal procedure and the impact of NICE guidance for the NHS will, it is hoped, encourage quality in clinical practice. All healthcare systems face budgetary constraints and the introduction of new technologies bring particular challenges. The launch of the new biological agents for the treatment of rheumatoid arthritis, into a speciality where previously relatively inexpensive agents were prescribed, raises questions concerning managed introduction and reimbursement.
本文讨论了英国参与新药管理引进的各机构的作用，尤其关注了国家临床优化研究所（NICE）的工作。文中探讨了英国国民医疗服务体系（NHS）确定具有重大临床、财务和服务意义的关键新药技术的过程。这包括NICE选择评估产品的决策过程。希望NICE的评估程序及其指南对NHS的影响能够促进临床实践的质量提升。所有医疗保健系统都面临预算限制，而新技术的引入带来了特殊挑战。用于治疗类风湿性关节炎的新型生物制剂被引入到一个此前一直使用相对廉价药物的专科领域，这引发了有关管理引进和报销的问题。
